Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on; Boehringer Ingelheim’s November 2017 announcement that the European Commisssion had granted approval for the company’s adalimumab biosimilar, Cyltezo; the FDA’s acceptance of a regulatory submission for Sandoz’s rituximab biosimilar (GP2013), marketed in Europe as Rixathon/Riximyo since June 2017; and Celltrion’s development of a subcutaneous infliximab biosimilar.
How do KOLs perceive Boehringer Ingelheim’s adalimumab biosimilar, Cyltezo?
With three adalimumab biosimilars now approved in Europe, what concerns do prescribers have with regard to multiple biosimilar versions becoming available?
How do KOLs view Sandoz’s Rixathon, the second rituximab biosimilar to enter the RA space in Europe?
Celltrion is currently developing a subcutaneously administered infliximab biosimilar, but what need is there currently for a subcutaneous version of this product?
What concerns might prescribers have regarding Celltrion’s subcutaneous infliximab biosimilar?